Gladman, Dafna D
Kavanaugh, Arthur
Gómez-Reino, Juan J
Wollenhaupt, Jürgen
Cutolo, Maurizio
Schett, Georg
Lespessailles, Eric
Guerette, Benoit
Delev, Nikolay
Teng, Lichen
Edwards, Christopher J
Birbara, Charles A
Mease, Philip J
Clinical trials referenced in this document:
Documents that mention this clinical trial
Incidence of infections in patients with psoriatic arthritis and axial spondyloarthritis treated with biological or targeted disease-modifying agents: a systematic review and meta-analysis of randomised controlled trials, open-label studies and observational studies
https://doi.org/10.1136/rmdopen-2023-003064
Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial
https://doi.org/10.1016/s0140-6736(12)60642-4
Therapeutic benefit of apremilast on enthesitis and dactylitis in patients with psoriatic arthritis: a pooled analysis of the PALACE 1–3 studies
https://doi.org/10.1136/rmdopen-2018-000669
Apremilast Long-Term Safety Up to 5 Years from 15 Pooled Randomized, Placebo-Controlled Studies of Psoriasis, Psoriatic Arthritis, and Behçet’s Syndrome
https://doi.org/10.1007/s40257-023-00783-7
Documents that mention this clinical trial
Incidence of infections in patients with psoriatic arthritis and axial spondyloarthritis treated with biological or targeted disease-modifying agents: a systematic review and meta-analysis of randomised controlled trials, open-label studies and observational studies
https://doi.org/10.1136/rmdopen-2023-003064
Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial
https://doi.org/10.1016/s0140-6736(12)60642-4
Therapeutic benefit of apremilast on enthesitis and dactylitis in patients with psoriatic arthritis: a pooled analysis of the PALACE 1–3 studies
https://doi.org/10.1136/rmdopen-2018-000669
Apremilast Long-Term Safety Up to 5 Years from 15 Pooled Randomized, Placebo-Controlled Studies of Psoriasis, Psoriatic Arthritis, and Behçet’s Syndrome
https://doi.org/10.1007/s40257-023-00783-7
Documents that mention this clinical trial
Incidence of infections in patients with psoriatic arthritis and axial spondyloarthritis treated with biological or targeted disease-modifying agents: a systematic review and meta-analysis of randomised controlled trials, open-label studies and observational studies
https://doi.org/10.1136/rmdopen-2023-003064
Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial
https://doi.org/10.1016/s0140-6736(12)60642-4
Therapeutic benefit of apremilast on enthesitis and dactylitis in patients with psoriatic arthritis: a pooled analysis of the PALACE 1–3 studies
https://doi.org/10.1136/rmdopen-2018-000669
Apremilast Long-Term Safety Up to 5 Years from 15 Pooled Randomized, Placebo-Controlled Studies of Psoriasis, Psoriatic Arthritis, and Behçet’s Syndrome
https://doi.org/10.1007/s40257-023-00783-7
Documents that mention this clinical trial
Incidence of infections in patients with psoriatic arthritis and axial spondyloarthritis treated with biological or targeted disease-modifying agents: a systematic review and meta-analysis of randomised controlled trials, open-label studies and observational studies
https://doi.org/10.1136/rmdopen-2023-003064
Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial
https://doi.org/10.1016/s0140-6736(12)60642-4
Therapeutic benefit of apremilast on enthesitis and dactylitis in patients with psoriatic arthritis: a pooled analysis of the PALACE 1–3 studies
https://doi.org/10.1136/rmdopen-2018-000669
Apremilast Long-Term Safety Up to 5 Years from 15 Pooled Randomized, Placebo-Controlled Studies of Psoriasis, Psoriatic Arthritis, and Behçet’s Syndrome
https://doi.org/10.1007/s40257-023-00783-7
Documents that mention this clinical trial
Incidence of infections in patients with psoriatic arthritis and axial spondyloarthritis treated with biological or targeted disease-modifying agents: a systematic review and meta-analysis of randomised controlled trials, open-label studies and observational studies
https://doi.org/10.1136/rmdopen-2023-003064
Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial
https://doi.org/10.1016/s0140-6736(12)60642-4
Therapeutic benefit of apremilast on enthesitis and dactylitis in patients with psoriatic arthritis: a pooled analysis of the PALACE 1–3 studies
https://doi.org/10.1136/rmdopen-2018-000669
Apremilast Long-Term Safety Up to 5 Years from 15 Pooled Randomized, Placebo-Controlled Studies of Psoriasis, Psoriatic Arthritis, and Behçet’s Syndrome
https://doi.org/10.1007/s40257-023-00783-7
Documents that mention this clinical trial
Incidence of infections in patients with psoriatic arthritis and axial spondyloarthritis treated with biological or targeted disease-modifying agents: a systematic review and meta-analysis of randomised controlled trials, open-label studies and observational studies
https://doi.org/10.1136/rmdopen-2023-003064
Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial
https://doi.org/10.1016/s0140-6736(12)60642-4
Therapeutic benefit of apremilast on enthesitis and dactylitis in patients with psoriatic arthritis: a pooled analysis of the PALACE 1–3 studies
https://doi.org/10.1136/rmdopen-2018-000669
Apremilast Long-Term Safety Up to 5 Years from 15 Pooled Randomized, Placebo-Controlled Studies of Psoriasis, Psoriatic Arthritis, and Behçet’s Syndrome
https://doi.org/10.1007/s40257-023-00783-7
Funding for this research was provided by:
Celgene Corporation